Literature DB >> 23264393

Beclin 1 enhances proteasome inhibition-mediated cytotoxicity of thyroid cancer cells in macroautophagy-independent manner.

Hai-Yan Zhang1, Zhen-Xian Du, Xin Meng, Zhi-Hong Zong, Hua-Qin Wang.   

Abstract

CONTEXT: The ubiquitin-proteasome system and macroautophagy are two major pathways for intracellular protein degradation. Emerging lines of evidence have shown that blockade of ubiquitin-proteasome system by proteasome inhibitors activates macroautophagy.
OBJECTIVE: The purpose of this study was to determine the involvement of autophagy essential gene Beclin 1 in cytotoxicity of thyroid cancer cells mediated by proteasome inhibitors.
DESIGN: Autophagy was measured by acidic-trophic dye staining and EGF-LC3 distribution using fluorescence microscopy, as well as LC3-II transition using Western blot. To ascertain the effect of Beclin 1, cells were transfected with Beclin 1 plasmid or shRNA against Beclin 1. Cell viability and apoptotic cells were measured using MTT assay and flow cytometry, respectively.
RESULTS: Proteasome inhibitors decreased Beclin 1 expression. In addition, treatment with PI3K inhibitors 3-MA or wortmannin, as well as knockdown of Beclin 1 expression, was unable to affect autophagic responses mediated by proteasome inhibitors. Overexpression of Beclin 1 enhanced proteasome inhibitor-mediated cytotoxicity of thyroid cancer cells via suppression of survivin.
CONCLUSIONS: Proteasome inhibitors cause Beclin 1-independent macroautophagic responses of thyroid cancer cells in a Beclin 1-independent manner. Beclin 1 possesses autophagy-independent antitumoral effects upon exposure of thyroid cancer cells to proteasome inhibitors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23264393     DOI: 10.1210/jc.2012-2679

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Autophagy in thyroid cancer: present knowledge and future perspectives.

Authors:  Romana T Netea-Maier; Viola Klück; Theo S Plantinga; Johannes W A Smit
Journal:  Front Endocrinol (Lausanne)       Date:  2015-02-18       Impact factor: 5.555

Review 2.  Positioning of proteasome inhibitors in therapy of solid malignancies.

Authors:  Margot S F Roeten; Jacqueline Cloos; Gerrit Jansen
Journal:  Cancer Chemother Pharmacol       Date:  2017-11-28       Impact factor: 3.333

3.  Combined inhibition of autophagy and Nrf2 signaling augments bortezomib-induced apoptosis by increasing ROS production and ER stress in pancreatic cancer cells.

Authors:  Xu Li; Meng Liang; Jianxin Jiang; Ruizhi He; Min Wang; Xingjun Guo; Ming Shen; Renyi Qin
Journal:  Int J Biol Sci       Date:  2018-07-27       Impact factor: 6.580

4.  Isolation, Characterization, and Autophagy Function of BECN1-Splicing Isoforms in Cancer Cells.

Authors:  Chinmay Maheshwari; Chiara Vidoni; Rossella Titone; Andrea Castiglioni; Claudia Lora; Carlo Follo; Ciro Isidoro
Journal:  Biomolecules       Date:  2022-08-02

5.  Noncoding RNA blockade of autophagy is therapeutic in medullary thyroid cancer.

Authors:  Justin S Gundara; JingTing Zhao; Anthony J Gill; James C Lee; Leigh Delbridge; Bruce G Robinson; Catriona McLean; Jonathan Serpell; Stan B Sidhu
Journal:  Cancer Med       Date:  2014-12-08       Impact factor: 4.452

6.  Divergent roles of BECN1 in LC3 lipidation and autophagosomal function.

Authors:  Ruina He; Jingyu Peng; Pengfei Yuan; Fang Xu; Wensheng Wei
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

7.  Induction of epithelial-mesenchymal transition (EMT) by Beclin 1 knockdown via posttranscriptional upregulation of ZEB1 in thyroid cancer cells.

Authors:  Si Li; Hai-Yan Zhang; Zhen-Xian Du; Chao Li; Ming-Xin An; Zhi-Hong Zong; Bao-Qin Liu; Hua-Qin Wang
Journal:  Oncotarget       Date:  2016-10-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.